CD276 and neoplasm: Specifically, we developed two-site, that is, cysteine and lysine, co-conjugation technologies to link a chemotherapeutic agent for direct tumor cell killing and a Toll-like receptor dual agonist for tumoral immunity enhancement to our humanized anti-CD276 (B7-H3) mAb.